Lazard Asset Management LLC Buys New Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)

Lazard Asset Management LLC purchased a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 82,005 shares of the company’s stock, valued at approximately $4,390,000. Lazard Asset Management LLC owned approximately 0.16% of Janux Therapeutics at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of JANX. Integral Health Asset Management LLC acquired a new stake in shares of Janux Therapeutics during the fourth quarter worth about $10,708,000. Janus Henderson Group PLC boosted its holdings in shares of Janux Therapeutics by 41.2% in the fourth quarter. Janus Henderson Group PLC now owns 3,562,402 shares of the company’s stock valued at $190,617,000 after acquiring an additional 1,038,996 shares during the period. Ensign Peak Advisors Inc boosted its holdings in shares of Janux Therapeutics by 7.0% in the fourth quarter. Ensign Peak Advisors Inc now owns 142,300 shares of the company’s stock valued at $7,619,000 after acquiring an additional 9,300 shares during the period. Farallon Capital Management LLC purchased a new position in shares of Janux Therapeutics during the fourth quarter worth approximately $2,570,000. Finally, Fred Alger Management LLC acquired a new position in shares of Janux Therapeutics in the 4th quarter valued at $1,258,000. 75.39% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Andrew Hollman Meyer sold 3,334 shares of the company’s stock in a transaction on Monday, April 21st. The stock was sold at an average price of $30.00, for a total value of $100,020.00. Following the sale, the insider now directly owns 82,139 shares in the company, valued at $2,464,170. This represents a 3.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ra Capital Management, L.P. purchased 341,742 shares of the stock in a transaction dated Wednesday, March 5th. The shares were purchased at an average price of $30.64 per share, with a total value of $10,470,974.88. Following the completion of the acquisition, the director now owns 9,658,988 shares of the company’s stock, valued at approximately $295,951,392.32. This represents a 3.67% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders sold 10,001 shares of company stock worth $313,964. Company insiders own 8.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on JANX. Scotiabank decreased their price target on shares of Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating for the company in a research note on Friday, February 28th. HC Wainwright reiterated a “buy” rating and set a $70.00 target price on shares of Janux Therapeutics in a research note on Monday, March 3rd. Finally, Wedbush restated an “outperform” rating and issued a $76.00 price target (up previously from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Janux Therapeutics has a consensus rating of “Buy” and a consensus price target of $95.25.

Janux Therapeutics Stock Performance

NASDAQ:JANX opened at $23.27 on Friday. Janux Therapeutics, Inc. has a 1 year low of $22.48 and a 1 year high of $71.71. The stock has a fifty day moving average price of $28.76 and a two-hundred day moving average price of $40.94. The stock has a market capitalization of $1.38 billion, a price-to-earnings ratio of -19.89 and a beta of 3.24.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.05. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. On average, analysts predict that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.